Finerenone is a selective mineralocorticoid receptor (MR) blocker:
- inhibits the effects of mineralocorticoids like aldosterone and cortisol when the MR is overactivated
FINEARTS-HF study
- double-blind trial
- randomly assigned patients with heart failure and a left ventricular ejection fraction of 40% or greater, in a 1:1 ratio, to receive finerenone (at a maximum dose of 20 mg or 40 mg once daily) or matching placebo, in addition to usual therapy
- primary outcome was a composite of total worsening heart failure events (with an event defined as a first or recurrent unplanned hospitalization or urgent visit for heart failure) and death from cardiovascular causes
Study results:
- over a median follow-up of 32 months, 1083 primary-outcome events occurred in 624 of 3003 patients in the finerenone group, and 1283 primary-outcome events occurred in 719 of 2998 patients in the placebo group (rate ratio, 0.84; 95% confidence interval [CI], 0.74 to 0.95; P=0.007)
- total number of worsening heart failure events was 842 in the finerenone group and 1024 in the placebo group (rate ratio, 0.82; 95% CI, 0.71 to 0.94; P=0.006)
- percentage of patients who died from cardiovascular causes was 8.1% and 8.7%, respectively (hazard ratio, 0.93; 95% CI, 0.78 to 1.11). Finerenone was associated with an increased risk of hyperkalemia and a reduced risk of hypokalemia
Study authors concluded that:
- patients with heart failure and mildly reduced or preserved ejection fraction, finerenone resulted in a significantly lower rate of a composite of total worsening heart failure events and death from cardiovascular causes than placebo
An analysis of FINEARTS-HF found those with recent worsening heart failure event had a higher risk of recurrent heart failure events/CV death, & the absolute benefit of finerenone may be higher in these patients (2).
Reference:
- Solomon SD et al. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. NEJM September 1, 2024.
- Desai AS et al. Finerenone in Patients With a Recent Worsening Heart Failure Event: The FINEARTS-HF Trial. JACC 29 September 2024.